Treatment of hyperproliferative conditions of body surfaces

Details Treatment of hyperproliferative conditions of body surfaces Treatment of hyperproliferative conditions of body surfaces

2008-03-18

2008-03-18

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S006400

Reexamination Certificate

active

10486648

ABSTRACT:
The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis. In particular the invention relates to treatment of psoriasis, and preferably to treatment of psoriasis with valrubicin topically applied.

REFERENCES:
patent: 4946683 (1990-08-01), Forssen
patent: 6231855 (2001-05-01), Ghione et al.
patent: 6555095 (2003-04-01), Garrison
Onrust, et al., “Valrubicin”,Drugs&Aging, vol. 15 (1), pp. 69-75, Jul. 1999.
Caplus Abstract 1991:415497 (1991) of Katada, T. “Effectiveness of doxorubicin hydrochloride (adriamycin) ointment on malignant skin lesions”, Sei Marianna Ika Daikaku Zasshi, 18(5):818-31 (1990).
Dantchev, et al., “Comparative Microscopic Study of Cardiotoxicity And Skin Toxicity Of Anthracycline Analogs”,Biomedicine&Pharmacotherapy, vol. 38, pp. 322-328, 1984.
Dantchev, et al., “Electron Microscopic Studies of the Heart and Light Microscopic Studies of the Skin After Treatment of Golden Hamsters With Adriamycin, Detorubicin, AD-32, and Aclacinomycin”,Cancer Treatment Reports, vol. 63, pp. 875-888, May 1979.
Dantchev, et al., “Ultrastructural Study of the Cardiotoxicity and Light-Microscopic Findings of the Skin After Treatment of Golden Hamsters with Seven Different Anthracyclines”,Recent Results Cancer Res., vol. 74, pp. 223-249, 1980.
Sweatman, et al., “Pharmacologic rationale for intravesicalN-Trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study”,Cancer Chemother Pharmacol., vol. 28, pp. 1-6, 1991.
Anthra Pharmaceuticals, Inc., “Valstar™ (valrubicin) Sterile Solution for Intravesical Instillation”, FDA NDA 20,892, pp. 1-11, 2001.

Affiliated with

Also associated with

Rating

Treatment of hyperproliferative conditions of body surfaces does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of hyperproliferative conditions of body surfaces, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hyperproliferative conditions of body surfaces will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3918277